Latest News and Press Releases
Want to stay updated on the latest news?
-
DENVER, Nov. 14, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce...
-
Revenue increased 192% to $15.3 million compared to $5.3 million in the prior year period Boca Raton, FL, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Bright Mountain Media, Inc. (OTCQB: BMTM)...
-
Completed NASDAQ listing Launched Smurfs & Zoonicorn Sip with Me® cups Multi-year license agreements JUPITER, FL, Nov. 14, 2023 (GLOBE NEWSWIRE) -- SRM Entertainment, Inc. (Nasdaq:...
-
Record Sales of $12.7 million for the Third Quarter; 120% Year-Over-Year Growth Record Gross Margin of $4.6 million for the Quarter; 149% Year-Over-Year Growth HOLLYWOOD, FL, Nov. 14, 2023 (GLOBE...
-
Revenues Increase to $3.3 Million and $9.9 Million from $1.3 Million and $4.9 Million for the Comparable Three- and Nine-Month Reporting Periods, Respectively MINNEAPOLIS, Nov. 14, 2023 (GLOBE...
-
Advances Non-Viral DNA-Mediated Cancer Immunotherapy and Next-Generation Vaccine Programs, with More Potent and Durable Immunity, with Multiple Near-Term Milestones Conference Call Begins...
-
Record Q3 Revenues Grow 64% to a Company Quarterly Record $17.5 million Company Provides Q4 2023 Revenue Outlook of $19 to $21 million SAN DIEGO, CA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- RYVYL Inc....
-
NEXGEL Reports Record Third Quarter 2023 Revenue of $1.2 Million, an Increase of 115% Year-Over-Year
Gross profit margin improved sequentially to 28.2% in Q3 as compared to 15.0% in Q2 LANGHORNE, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a...
-
Enrollment underway in Phase 1 trial with novel protease inhibitor CDI-988, the first potential dual coronavirus-norovirus oral antiviralDosing expected to begin later this year in Phase 2a human...
-
– Transformational transaction jumpstarts development pipeline into high-value inflammatory bowel disease (IBD) market – Lead program, PALI-2108, oral prodrug therapy for the treatment...